Better Buy: AbbVie vs. Johnson & Johnson
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are stalwart companies that are in a lot of investors' portfolios. Analysts almost always preach diversification, and these two healthcare stocks bring balance in their own right.
AbbVie is strictly pharmaceutical, but its recent purchase of Allergan really broadens its pipeline beyond the world's top-selling drug, Humira, which treats many auto-immune disorders. Pharmaceutical sales make up slightly more than half of Johnson & Johnson's revenue with its consumer health and medical devices bringing in the rest of its sales.
There's something to be said for sheer size. AbbVie has 47,000 employees and raked in $33.3 billion of revenue last year. The company anticipates likely revenue of $50 billion a year with Allergan under its wing. Johnson & Johnson has more than 132,000 employees and made $82 billion in revenue in fiscal 2019.
Source Fool.com
